Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children
Jean Li-Kim-Moy, Nicholas Wood, Cheryl Jones, Kristine Macartney, Robert Booy
PEDIATRIC INFECTIOUS DISEASE JOURNAL | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
BACKGROUND: Comparing postvaccination fever rates in pediatric influenza vaccine clinical trials is difficult due to variability in how fever is reported. The impact of vaccine-related fever and antipyretic use on trivalent influenza vaccine immunogenicity in children is also unclear. METHODS: In this pilot study, we used individual-level data provided by GlaxoSmithKline from 3 pediatric clinical trials of GlaxoSmithKline versus comparator trivalent influenza vaccine. We explored a primary study (NCT00764790), the largest trial involving young children (6-35 months, n = 3317), and further explored key findings in the 2 other trials (3-17 years, NCT00980005; 6 months to 17 years, NCT00383123)..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) Career Development fellowship
N.W. is supported by a National Health and Medical Research Council (NHMRC) Career Development fellowship (APP1063629). N.W. has been an investigator on industry supported (GlaxoSmithKline) investigator initiated trials. No personal funds were received during the conduct of these studies. R.B. has worked with several manufacturers of influenza vaccines in an advisory capacity, as a researcher on vaccines and as presenter of academic information at conferences and occasionally as an Advisory Board member. He has received support to travel and attend such conferences and meetings from BioCSL/Seqirus, GlaxoSmithKline, Sanofi, Novartis and Medimmune/Astra Zeneca. Funding and honoraria are paid directly to a research account at The Children's Hospital at Westmead and are not personally accepted by R.B. The other authors have no conflicts of interest to disclose.